



# **EFS Site Best Practices Workshop**

Event Materials

**March 6-7, 2019**

**MDIC Offices  
1501 Wilson Blvd.  
Arlington, VA 22209**



---

## EFS Site Best Practices

---

Location: MDIC Offices – 1501 Wilson Blvd Suite 910 Arlington, VA 22209

Date: March 6 - 7, 2019

---

### Wednesday, March 6<sup>th</sup>, 2019

7:30 AM Coffee, Tea, Rolls & Fruit

8:00 AM Welcome

8:05 AM EFS Overview

8:15 AM EFS: Value to Innovation

8:25 AM EFS Best Practices: Importance of Identifying Them

Chip Hance (MDIC Board)

Dr. Andy Farb (FDA)

Rick Geoffrion (Mitralign)

Dr. David Holmes (Mayo Clinic)

**8:35 AM - 10:15 AM** **Session I: Managing Risk, SAEs & IRB Reporting**

**Session Leaders**

Megan Mueller (Medtronic)

Jennifer Thomas (BS&W)

8:35 AM - Panel Discussion: Topics

9:20 AM Site Risk Tolerance: Impacts on Start-up and Enrollment  
Monitoring and Quality Assurance

AE Reporting:

- IRB Timelines, Policies and Expectations
- SAEs: Identification and Response

Safety Boards and Committees:

- Local vs. Central IRBs Reporting and Engagement
- Managing communications: DSMB, IRB and FDA

**Panelists:**

Dr. Martin Leon (Columbia UMC)

Kate Stohlman (Corvia)

Katherine Kumar (4C Medical)

Kristi DeHaai (UVA)

Dr. Seth Bilazarian (Abiomed)

9:20 AM - Open Discussion / Q&A

**10:15 AM Break**

**10:30 AM - 11:45 AM** **Session II: Timely & Effective Contracting**

**Session Leaders:**

Jaime Walkowiak (BS&W)

Blessie Concepcion (BSCI)

10:30 AM - Panel Discussion: Topics

11:15 AM Contracting Background: Creating the EFS Master CTA

Case Examples: EFS Master CTA in Practice

- Implementation at your Organization
- Use of current Industry Master CTAs

Getting to "Yes": Tips to Mitigate Risk & Access Decision-makers

EFS Start/Stop Communications: e.g. for device redesign, etc.

**Panelists:**

Chris Cain (Conformal Medical)

Sarah Briner (W.L. Gore)

Tiffany Sharkoski (UPenn)

Dr. Andy Farb (FDA)

11:15 AM - Open Discussion / Q&A

11:45 AM

<b>11:45 AM - 12:45 PM</b>	<b>Lunch &amp; Site Presentations: Learnings from Sites Achieving “60/60/60” or Better</b>	
12:00 PM	<u>Site Learnings: Oregon Health &amp; Sciences University (OHSU)</u>	Beth Wilson
12:15 PM	<u>Site Learnings: Northwestern University</u>	Lynne Goodreau
12:30 PM	<u>Open Discussion / Q&amp;A</u>	
<b>12:45 PM - 2:15 PM</b>	<b><u>Session III: Budgeting between EFS Sites and Sponsors</u></b>	<b><u>Session Leaders:</u></b> Kathy Kioussopoulos (Franciscan) Gretchen Wild (Abbott)
12:45 PM - 1:30 PM	<u>Panel Discussion: Topics</u> Differences from Pivotal trials: <ul style="list-style-type: none"> <li>- Budgeting for Unknowns, AEs, etc.</li> <li>- Standard of Care Definitions</li> </ul> Alternative Payment Emphasis: Start-up vs. Per Patient Fees Improvement Opportunities: Streamlining Site and Sponsor Budget Negotiations Site & Sponsor Budgeting Differences: A Case Example	<b><u>Panelists:</u></b> Kristen Chionh (BS&W) Susanne McGlothlin (OHSU) Manal Al-Suqi (UMD) Kim Clinton (UPenn)
1:30 PM - 2:15 PM	<u>Open Discussion / Q&amp;A</u>	
<b>2:15 PM</b>	<b>Break</b>	
<b>2:30 PM - 4:00 PM</b>	<b><u>Session IV: EFS Staffing and Resources</u></b>	<b><u>Session Leaders:</u></b> Dr. Tamim Nazif (Columbia UMC) Lynne Goodreau (Northwestern)
2:30 PM - 3:10 PM	<u>Panel Discussion: Topics</u> Institution Fit: How do we know if an EFS is right for us? <ul style="list-style-type: none"> <li>- Physician Champions: Assessing protocols, patient populations and other considerations</li> <li>- PI Engagement/Oversight for EFS</li> </ul> Site Considerations: Special considerations for EFS trials <ul style="list-style-type: none"> <li>- Data Collection: Rigor &amp; Requirements</li> <li>- Staff Training &amp; Experience</li> </ul>	<b><u>Panelists:</u></b> Dr. Mike Bowdish (USC) Ann Marie Chikowski (Main Line Health) Susmitha Gadde (Houston Methodist) Andrew Garcia (W.L. Gore) Allison Hawke (Dartmouth)
3:20 PM – 4:00 PM	<u>Open Discussion / Q&amp;A</u>	
<b>4:00 PM</b>	<b>Wrap-Up</b>	Chip Hance / Liliana Rincon-Gonzalez (MDIC)
<b>6:00 PM – 8:00 PM</b>	<b><u>Evening Dinner &amp; Session:</u></b> Location: Hyatt Centric Hotel 1325 Wilson Boulevard, Arlington, VA, 22209	<b><u>Evening Speaker:</u></b>
6:15 PM – 6:45 PM	Session: “EFS in the context of FDA Priorities and Initiatives”	Dr. Bram Zuckerman Director, Division of Cardiovascular Devices, USFDA
7:00 PM	Dinner	
8:00 PM	Wrap-up	Liliana Rincon-Gonzalez (MDIC)

**Thursday, March 7<sup>th</sup>, 2019**

7:30 AM Coffee, Tea, Rolls & Fruit

**8:00 AM - 9:45 AM** **Session V: Patient Identification, Enrollment & Retention**

**Session Leaders:**

Sara Vidmar (preCARDIA)  
Necole Kell (BS&W)

8:05 AM – Patient Experience Presentation: EFS vs. Pivotal Studies

Necole Kell (BS&W)

8:15 AM

8:15 AM – Panel Discussion: Topics

**Panelists:**

9:00 AM Site Tools: Outsourcing Recruitment, IRB Pre-Screening Waivers, etc.

Aarti Kenjale (Duke)

Mark Pierre (Enspire DBS)

Patient Expectations & Tools:

Sarah Fishbein (OHSU)

- Managing complexity, visit adherence, etc.

Melissa Broich (4C Medical)

- Beyond Inclusion/Exclusion: Identifying needs for childcare, travel, etc.

Site Engagement: Avoiding Competitive Enrollments

9:00 AM -

9:45 AM Open Discussion / Q&A

**9:45 AM Break**

**10:00 AM – 11:30 AM** **Session VI: Coverage Determinations & Site Budgets**

**Session Leaders:**

Dr. Rochelle Fink (CMS/FDA)  
Jill Trekell (Edwards)

10:00 AM – Panel Discussion: Topics

**Panelists:**

10:45 AM Coverage Determination Roles: CMS, Sponsors & Sites

Michael Parides (Montefiore)

- FDA: EFS designation (Category A/B)

Lauren Baker (BBA)

- CMS: Coverage of Standard of Care in EFS

Patti Spencer (Intermountain)

“Standard of Care” Determinations:

Wini Wu

- Site & Sponsor Budget Discussions

(Strategic Regulatory Partners)

- Variations in “Standard of Care” across the U.S.

Changfu Wu (FDA)

- National vs. Local Coverage

Potential Waivers on CMS Approval to Expedite Start-up

Coverage: A Case Study on Building your Budget

10:45 AM -

11:30 AM Open Discussion / Q&A

**11:30 AM – 12:00 PM** **Wrap-up, Workstreams & Next Steps**

Jaime Walkowiak (BS&W)

Dan Schwartz (MDIC)

**EFS**

**Best Practices Workshop**

**Attendees**

1.	<b>Katherine Kumar</b>	Executive Vice President	4C Medical
2.	<b>Melissa Broich</b>	Director, Clinical Affairs	4C Medical
3.	<b>Gretchen Wild</b>	Director, Clinical Research	Abbott
4.	<b>Seth Bilazarian</b>	Chief Medical Officer	Abiomed
5.	<b>Carrie Cameron</b>	Senior Clinical Program Manager	Abiomed
6.	<b>Michael Zapien</b>	VP Clinical Affairs	Ancora Heart
7.	<b>Jaime Walkowiak</b>	COO	Baylor Scott & White
8.	<b>Jennifer Thomas</b>	Director of Clinical Research	Baylor Scott & White
9.	<b>Kristen Chionh</b>	Director of Clinical Research, CV	Baylor Scott & White
10.	<b>Makshita Luthra</b>	Project Analyst – Clinical Research	Baylor Scott & White
11.	<b>Necole Kell</b>	Clinical Research Nurse	Baylor Scott & White
12.	<b>Lauren Baker</b>	CEO	Boston Biomedical Associates
13.	<b>Michelle Nivala</b>	Principal Regulatory Affairs Specialist	Boston Scientific
14.	<b>Blessie Concepcion</b>	Director Global Clinical Trials	Boston Scientific
15.	<b>Tricia Pearce</b>	Associate Director, CTO	Cedars-Sinai
16.	<b>Nicole Leonard</b>	VP & Associate Dean, Research	Cedars-Sinai
17.	<b>Anna Teresa Valencia</b>	Senior Director, Clinical Research Operations	College of Medicine, UoA
18.	<b>Martin Leon</b>	Mallah Family Professor of Cardiology	Columbia UMC
19.	<b>Tamim Nazif</b>	Assistant Professor of Medicine	Columbia UMC
20.	<b>Chris Cain</b>	VP, Clinical & Regulatory Affairs	Conformal Medical, Inc.
21.	<b>Kate Stohlman</b>	VP, Quality & Regulatory Affairs	Corvia Medical
22.	<b>Allison J. Hawke</b>	Research Operations Manager	Dartmouth-Hitchcock Heart and Vascular Center
23.	<b>Aarti Kenjale</b>	Sr. Director, Clinical Affairs	Duke University Heart Center
24.	<b>Jill Trekell</b>	Director, Office of Product Evaluation and Quality Office of Neurological and Physical Medicine Devices	Edwards Lifesciences
25.	<b>Mark Pierre</b>	Director Clinical and Regulatory Affairs	Enspire DBS Therapy
26.	<b>Kathy Kiousopoulos</b>	Director Research Administration	Franciscan Alliance
27.	<b>Jodi Akin</b>	CEO	Hawthorne
28.	<b>Susmitha Gadde</b>	Research Administrative Director	Houston Methodist

<b>29.</b>	<b>Anne Marie Chikowski</b>	Division Manager, Cardiovascular Research	Main Line Health
<b>30.</b>	<b>Dan Schwartz</b>	Director, Clinical Trial Sciences (acting)	MDIC
<b>31.</b>	<b>Liliana Rincon-Gonzalez</b>	Program Director Clinical Science	MDIC
<b>32.</b>	<b>Chip Hance</b>	Board of Directors	MDIC
<b>33.</b>	<b>Megan Mueller</b>	SVP, Regulatory Affairs	Metavention, Inc.
<b>34.</b>	<b>Megan Brandt</b>	SVP, Regulatory Affairs	Metavention, Inc.
<b>35.</b>	<b>Rick Geoffrion</b>	CEO	Mitralign
<b>36.</b>	<b>Michael Parides</b>	Chief, Division of Early Stage Technology and Exploration	Montefiore Medical Center
<b>37.</b>	<b>Lynne Goodreau</b>	Administrative Director, Bluhm CV Institute CTU	Northwestern University
<b>38.</b>	<b>Trae Reichert</b>	Contract Analyst	OHSU
<b>39.</b>	<b>Beth Wilson</b>		OHSU
<b>40.</b>	<b>Susanne McGlothlin</b>	Finance Administrator, Knight CV Institute	OHSU
<b>41.</b>	<b>Sarah Fishbein</b>	Lead Device Research Coordinator	OHSU
<b>42.</b>	<b>Sara Vidmar</b>	SVP, Clinical, Regulatory & Strategic Affairs	preCARDIA
<b>43.</b>	<b>Gerri O'Riordan</b>	Director of Clinical Research, CV	Stanford University Medical Center
<b>44.</b>	<b>Wini Wu</b>	Principal Advisor	Strategic Regulatory Partners
<b>45.</b>	<b>Manal Al-Suqi</b>	Clinical Research Operations Manager, Department of Cardiac Surgery	University of Maryland
<b>46.</b>	<b>Sarah Rubin</b>	Clinical Research PM	University of Maryland
<b>47.</b>	<b>Jessica Oakley</b>	Clinical Research PM	University of Maryland
<b>48.</b>	<b>Dan Menees</b>	Assistant Professor	University of Maryland
<b>49.</b>	<b>Stanley Chetcuti</b>	Professor	University of Maryland
<b>50.</b>	<b>Steven Bolling</b>	Professor of Medicine	University of Maryland
<b>51.</b>	<b>Kimberly Clinton</b>	Regulatory Manager	University of Pennsylvania
<b>52.</b>	<b>Tiffany Sharkoski</b>	Manager, Cardiovascular CRU	University of Pennsylvania
<b>53.</b>	<b>Karen Cooper</b>	Associate Director	University of Pennsylvania
<b>54.</b>	<b>Regina Hollister</b>	Valve Clinic Coordinator	UPMC Pinnacle
<b>55.</b>	<b>Anita Todd</b>	Cardiovascular Institute	UPMC Pinnacle
<b>56.</b>	<b>Kathryn O'Callaghan</b>	CDRH Assistant Director for Strategic Programs	US FDA

**March 6-7, 2019**  
MDIC Offices  
1501 Wilson Blvd Suite 901,  
Arlington, VA 22209

---

<b>57.</b>	<b>Changfu Wu</b>	Reviewer, Division of Cardiovascular Devices	US FDA
<b>58.</b>	<b>Andrew Farb</b>	Medical Officer & Senior Reviewer	US FDA
<b>59.</b>	<b>Bram Zuckerman</b>	Director, Division of CV Devices	US FDA
<b>60.</b>	<b>Rochelle Fink</b>	Senior Health Science Specialist	US FDA/CMS
<b>61.</b>	<b>Mike Bowdish</b>	Service Chief, Cardiac Surgery	USC Medical Center
<b>62.</b>	<b>China Green</b>	Clinical Research Coordinator	University of Virginia
<b>63.</b>	<b>Kristi DeHaai</b>	Compliance Coordinator, Health Sciences Research IRB	University of Virginia
<b>64.</b>	<b>Andrew Garcia</b>	Team Lead, Study Management	W.L. Gore & Associates

---